184954-75-4

Basic information

• Product Name: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE
• Synonyms: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE;1-N-Boc-cis-1,2-cyclohexyldiamine;1-N-Boc-1,2-cis-cyclohexyldiamine (Racemic);CarbaMic acid, (2-aMinocyclohexyl)-, 1,1-diMethylethyl ester, cis-;N-Boc-cis-1,2-cyclohexanediaMine;N-[(1R,2S)-2-aMinocyclohexyl]-, CarbaMic acid, 1,1-diMethylethyl ester;cis-N1-(tert-Butoxycarbonyl)-1,2-cyclohexanediaMine;Cis 1N-Boc-cyclohexane-1,2-diaMine
• CAS NO: 184954-75-4
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Mol File: 184954-75-4.mol

Chemical Properties

• Melting Point: 46 °C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE(184954-75-4)
• EPA Substance Registry System: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE(184954-75-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/39
• Hazardous Substances Data: 184954-75-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE is used as a building block for the synthesis of pharmaceuticals, leveraging its cyclohexyl backbone and amine groups to create a variety of medicinal compounds. The BOC protecting group allows for selective functionalization, which is crucial for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE serves as a key intermediate for the synthesis of various agrochemicals. Its structural features facilitate the creation of compounds with pesticidal or herbicidal properties, contributing to the development of effective crop protection agents.
Used in Organic Synthesis:
1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE is utilized as a versatile reagent in organic synthesis, particularly for the preparation of heterocyclic compounds. Its unique structure and the presence of the BOC protecting group make it suitable for the synthesis of complex organic molecules with potential applications in various fields, including materials science and specialty chemicals.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1436-59-5 cis-cyclohexane-1,2-diamine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 

Relevant articles and documents

From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis

Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structure-activity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.

Dramatic increase of quench efficiency in "spacerless" dimaleimide fluorogens

In this post-genomic era, new techniques are needed to cope with the task of assigning functional roles to the huge number of identified putative gene products. We have developed a minimalist labelling strategy based on the use of synthetic fluorogenic probe reagents that fluoresce only after their reaction with a target peptide sequence. The probe reagents have fluorescent cores and bear two maleimide groups, such that their latent fluorescence is quenched by a photoinduced electron transfer (PET) to the pendant maleimide groups, until both of these groups undergo a specific thiol addition reaction. The efficiency of the fluorescence quenching is critical to the practicality of this labelling method, and has been predicted to be related to the intramolecular distance between the fluorophore and the maleimide groups. We have conducted the first direct test of this hypothesis by preparing a series of novel fluorogens that differ only by the spacer moiety separating their coumarin fluorophore and their dimaleimide fragment. A striking correlation was observed between intramolecular distance and the fluorescence enhancement (FE) observed after reaction with two equivalents of thiol. Guided by this observation, we then designed 'spacerless' fluorogens, of which a dansyl derivative shows an FE ratio of >300, the largest recorded for dimaleimide fluorogens. The trends observed herein provide valuable lessons for subsequent fluorogen design, and the novel fluorogens developed in the course of this study are currently being applied to protein labelling applications.

Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists

We describe the design, synthesis, and evaluation of novel disubstituted cyclohexanes as potent CCR2 antagonists. Exploratory SAR studies led to the cis-disubstituted derivative 22, which displayed excellent binding affinity for CCR2 (binding IC50/s

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Immunomodulation with novel pharmaceutical compositions

The synthesis and use of a novel class of tumor necrosis factor (TNFα) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNFα and other involved cytokines. As pharmaceutic

Solid and Solution Phase Organic Syntheses of Oligomeric Thioureas

In order to study supramolecular architectures built from unnatural oligomeric and polymeric structures, one must first have an efficient synthetic strategy to produce them. Oligomers built from thiourea groups should form complex secondary and tertiary structures due to the hydrogenbonding capabilities of the thioureas. Herein, both solution and solid phase synthetic procedures that yield oligomeric thioureas are described. They rely on the coupling of an isothiocyanate with an amine to produce the thiourea linkage. The monomers are derived from simple diamines. Higher yields are achieved using the solid phase method due to the ability to easily monitor the extent of reaction, to use a large excess of reagent, and to perform purification after cleavage from the solid support. A variety of oligomers are given as examples. The procedure is quite general, should be easily extended to complex monomers, and will allow the investigation of intramolecular and intermolecular interactions.